SniperFx

Archives

  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • September 2022
  • August 2022
  • January 2022
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019

Categories

  • Analysis
  • Bonds
  • Crypto
  • Forex
  • Forex Trading
  • Ideas
  • Investing
  • News
  • Stocks
  • World
Subscribe
SniperFx
SniperFx
  • Bonds
  • Crypto
  • Forex
    • Forex Trading
  • Ideas
  • Investing
  • Stocks
  • World

GSK bets $2 billion on Bellus cough drug to soothe pipeline fears

  • admin
  • April 18, 2023

GSK plans to buy Canada-based drug developer Bellus Health Inc in an all-cash deal for $2 billion as the British drugmaker expands its bet on respiratory therapies.

The move to replenish its pipeline comes as GSK investors fret about whether there is enough in the medicine cabinet to keep the momentum going into the next decade with expected loss of patent protection of one of its key compounds.

At the heart of the deal – announced by both companies on Tuesday – is the experimental drug, camlipixant, which is in late-stage development as a treatment for refractory chronic cough (RCC).

The condition can cause patients to cough more than 900 times a day for more than a year. Some 10 million patients globally suffer from it and so far, there are no approved therapies.

GSK’s offer of $14.75 per share is more than double Bellus’ closing price of $7.26 on the Nasdaq on Monday.

The Bellus deal expands GSK’s existing respiratory portfolio, including Nucala and Trelegy, which generated more than a combined 3 billion pounds ($3.73 billion) last year.

Camlipixant is up against Merck’s rival drug, gefapixant, for RCC patients.

Early in 2022, gefapixant was denied approval by the U.S. regulator, which sought more information on its effectiveness – but the U.S. drugmaker is expected to resubmit an application for another review later this year.

Still, some analysts say camlipixant – should both drugs be eventually approved – could emerge as preferred option with a superior safety profile.

Jefferies analysts estimated camlipixant could generate peak U.S. sales of $1.2 billion, in a note earlier this month.

DEAL FLURRY

Investors are particularly interested in GSK’s future plans, given the pending loss of patent protection in 2027 for dolutegravir, the compound that forms part of four GSK’s HIV treatments, which puts more than 5 billion pounds of sales at risk.

The company is leaning in part on the prospects of its own vaccine targeted at the respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths a year, to at least partially offset that loss.

It has also announced a string of deals including a buyout of Affinivax and Sierra Oncology (NASDAQ:SRRA) to plug the gap.

Still, the company also has culled a handful of programmes from its pipeline in recent months and suffered setbacks in its marketed cancer drug portfolio.

Demand for its flagship blockbuster Shingrix vaccine is also expected to eventually saturate.

admin

Previous Article

‘Biggest mistake’ is not using tax loss harvesting Koinly head of tax

  • admin
  • April 18, 2023
View Post
Next Article

USDJPY Brief results and immediate prospects

  • admin
  • April 19, 2023
View Post
You May Also Like
View Post
  • Stocks

ISS backs Toyota shareholder proposal on climate disclosure

  • admin
  • May 28, 2023
View Post
  • Stocks

Lowe’s, AutoZone, Alibaba fall premarket; Yelp, Dick’s Sporting Goods rise

  • admin
  • May 23, 2023
View Post
  • Stocks

Blackstone acquires International Gemological Institute

  • admin
  • May 21, 2023
View Post
  • Stocks

Qualcomm to acquire Israeli auto-chip maker Autotalks

  • admin
  • May 8, 2023
View Post
  • Stocks

Assa, Spectrum Brands reach settlement with US on deal

  • admin
  • May 6, 2023
View Post
  • Stocks

Analysis-From tea to ketchup, some shelves lie empty as retailers struggle to predict demand

  • admin
  • May 3, 2023
View Post
  • Stocks

Australia stocks higher at close of trade; S&PASX 200 up 0.35%

  • admin
  • May 1, 2023
View Post
  • Stocks

US FDIC asks JPMorgan, PNC for final First Republic bids due Sunday

  • admin
  • April 29, 2023

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories
  • Analysis (33)
  • Bonds (70)
  • Crypto (90)
  • Forex (106)
  • Forex Trading (64)
  • Ideas (57)
  • Investing (61)
  • News (121)
  • Stocks (113)
  • World (200)
Recent Posts
  • ISS backs Toyota shareholder proposal on climate disclosure
  • Gold Prices at Risk of Deeper Correction on Surging Real Yields, USD Strength
  • US Dollar Weekly Outlook Will US Debt Ceiling Deal and Jobs Report Boost DXY Further
  • BTC’s Network Activity Has Started Recovering From Its May Lows
  • USDCHF double three Elliott Wave advance and next blue box area
SniperFx
  • Home
  • About Us
  • Contact
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
Forex & Crypto Updates

Input your search keywords and press Enter.